Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Paul Amminger

Showing results (1-10 of 143) with videos related to

Pageof 15
Sort By:
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 14, 2011
Update on ω-3 polyunsaturated fatty acids in early-stage psychotic disordersG Paul Amminger, Patrick D McGorry
Evidence-Based Mental Health|March 6, 2012
Review: limited evidence from two small trials suggests no improvement in ASD symptoms with short term ω-3 supplementationG Paul Amminger, Miriam R Schäfer
International Review of Psychiatry (Abingdon, England)|June 17, 2006
Bioactive lipids in schizophreniaGregor E Berger, Stefan Smesny, G Paul Amminger
Australian Journal of General Practice|July 31, 2022
Medicinal cannabis for the treatment of anxiety disordersMaximus Berger, G Paul Amminger, Iain S McGregor
Current Opinion in Psychiatry|May 3, 2011
Age of onset and timing of treatment for mental and substance use disorders: implications for preventive intervention strategies and models of carePatrick D McGorry, Rosemary Purcell, Sherilyn Goldstone, et al.
The Australian and New Zealand Journal of Psychiatry|May 11, 2023
The promise of the therapeutic use of cannabidiol for psychiatric disordersG Paul Amminger, Rebekah Street, Christopher G Davey, et al.
Schizophrenia Research|October 23, 2018
Current versus recently resolved attenuated psychotic symptoms: Same level of risk for transition to psychosis?Simon M Rice, Patrick D McGorry, G Paul Amminger, et al.
European Child & Adolescent Psychiatry|June 7, 2018
Natural killer cell function in adolescent and adult schizophrenic patientsFranz Resch, G Paul Amminger, Harald Aschauer, et al.
Methods in Molecular Biology (Clifton, N.J.)|March 29, 2020
Testing the Effects of Dietary Seafood Consumption on Depressive SymptomsMaximus Berger, G Paul Amminger, Robyn McDermott, et al.
Early Intervention in Psychiatry|August 24, 2013
Metabolic changes in first-episode early-onset schizophrenia with second-generation antipsychoticsBrian O'Donoghue, Miriam R Schäfer, Jana Becker, et al.
Pageof 15

Showing results (1-10 of 143) with videos related to

Sort By:
Pageof 15
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 14, 2011
Update on ω-3 polyunsaturated fatty acids in early-stage psychotic disordersG Paul Amminger, Patrick D McGorry
Evidence-Based Mental Health|March 6, 2012
Review: limited evidence from two small trials suggests no improvement in ASD symptoms with short term ω-3 supplementationG Paul Amminger, Miriam R Schäfer
International Review of Psychiatry (Abingdon, England)|June 17, 2006
Bioactive lipids in schizophreniaGregor E Berger, Stefan Smesny, G Paul Amminger
Australian Journal of General Practice|July 31, 2022
Medicinal cannabis for the treatment of anxiety disordersMaximus Berger, G Paul Amminger, Iain S McGregor
Current Opinion in Psychiatry|May 3, 2011
Age of onset and timing of treatment for mental and substance use disorders: implications for preventive intervention strategies and models of carePatrick D McGorry, Rosemary Purcell, Sherilyn Goldstone, et al.
The Australian and New Zealand Journal of Psychiatry|May 11, 2023
The promise of the therapeutic use of cannabidiol for psychiatric disordersG Paul Amminger, Rebekah Street, Christopher G Davey, et al.
Schizophrenia Research|October 23, 2018
Current versus recently resolved attenuated psychotic symptoms: Same level of risk for transition to psychosis?Simon M Rice, Patrick D McGorry, G Paul Amminger, et al.
European Child & Adolescent Psychiatry|June 7, 2018
Natural killer cell function in adolescent and adult schizophrenic patientsFranz Resch, G Paul Amminger, Harald Aschauer, et al.
Methods in Molecular Biology (Clifton, N.J.)|March 29, 2020
Testing the Effects of Dietary Seafood Consumption on Depressive SymptomsMaximus Berger, G Paul Amminger, Robyn McDermott, et al.
Early Intervention in Psychiatry|August 24, 2013
Metabolic changes in first-episode early-onset schizophrenia with second-generation antipsychoticsBrian O'Donoghue, Miriam R Schäfer, Jana Becker, et al.
Pageof 15